HLB announced that its U.S. subsidiary, Elevar Therapeutics, received notification from the U.S. Food and Drug Administration (FDA) on the 27th (local time) that a full review has commenced for the new drug application of "Lirafugratinib" as a second-line treatment for cholangiocarcinoma with FGFR2 fusion and rearrangement.


HLB's New Cholangiocarcinoma Drug Designated for FDA Priority Review View original image

Lirafugratinib has been designated for "Priority Review" by the FDA. This shortens the review period by four months compared to the standard 10-month review, meaning the approval decision for the new drug will be made by September 27. Elevar plans to focus all efforts on securing new drug approval and commercialization, as Lirafugratinib has demonstrated superior data compared to competing drugs.


Lirafugratinib achieved an objective response rate (ORR) of 47%, showing competitive efficacy compared to currently approved pan-FGFR inhibitors such as Pemigatinib (36%) and Futibatinib (42%). In terms of safety, it was found to be predictable and manageable through dose adjustments.



Donggun Kim, CEO of Elevar Therapeutics, stated, "The commencement of the full review and the shortened timeline due to Priority Review for Lirafugratinib are extremely encouraging signals for our corporate value. We will focus all our capabilities on achieving the major milestones of approval and commercialization of the liver cancer new drug by July, and the cholangiocarcinoma new drug by September. In addition, we will also accelerate the ongoing basket trial of Lirafugratinib as a tumor-agnostic anticancer therapy."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing